JP2020508995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508995A5 JP2020508995A5 JP2019544887A JP2019544887A JP2020508995A5 JP 2020508995 A5 JP2020508995 A5 JP 2020508995A5 JP 2019544887 A JP2019544887 A JP 2019544887A JP 2019544887 A JP2019544887 A JP 2019544887A JP 2020508995 A5 JP2020508995 A5 JP 2020508995A5
- Authority
- JP
- Japan
- Prior art keywords
- smarca2
- activity
- smarca4
- function
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022116375A JP2022136149A (ja) | 2017-02-28 | 2022-07-21 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464811P | 2017-02-28 | 2017-02-28 | |
| US62/464,811 | 2017-02-28 | ||
| US201762542241P | 2017-08-07 | 2017-08-07 | |
| US62/542,241 | 2017-08-07 | ||
| PCT/US2018/020124 WO2018160636A1 (en) | 2017-02-28 | 2018-02-28 | Inhibition of smarca2 for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116375A Division JP2022136149A (ja) | 2017-02-28 | 2022-07-21 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020508995A JP2020508995A (ja) | 2020-03-26 |
| JP2020508995A5 true JP2020508995A5 (enExample) | 2021-04-08 |
Family
ID=63371135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544887A Pending JP2020508995A (ja) | 2017-02-28 | 2018-02-28 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
| JP2022116375A Pending JP2022136149A (ja) | 2017-02-28 | 2022-07-21 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116375A Pending JP2022136149A (ja) | 2017-02-28 | 2022-07-21 | 癌の処置のためのｓｍａｒｃａ２の阻害 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200069669A1 (enExample) |
| EP (1) | EP3589289A4 (enExample) |
| JP (2) | JP2020508995A (enExample) |
| KR (1) | KR20190140438A (enExample) |
| CN (1) | CN110366418A (enExample) |
| AU (2) | AU2018227774A1 (enExample) |
| BR (1) | BR112019017851A2 (enExample) |
| CA (1) | CA3054682A1 (enExample) |
| CL (1) | CL2019002427A1 (enExample) |
| IL (1) | IL268676A (enExample) |
| MX (2) | MX2019010149A (enExample) |
| SG (2) | SG11201907420VA (enExample) |
| WO (1) | WO2018160636A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| JP2020508995A (ja) * | 2017-02-28 | 2020-03-26 | エピザイム，インコーポレイティド | 癌の処置のためのｓｍａｒｃａ２の阻害 |
| US11807623B2 (en) | 2017-11-30 | 2023-11-07 | Arrakis Therapeutics, Inc. | Nucleic acid-binding photoprobes and uses thereof |
| US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| WO2020106915A1 (en) * | 2018-11-21 | 2020-05-28 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| WO2020160100A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160196A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP7696301B2 (ja) * | 2019-06-27 | 2025-06-20 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | タンパク質分解のための化合物、組成物、および方法 |
| BR112022004573A2 (pt) * | 2019-09-12 | 2022-06-07 | Aurigene Discovery Tech Ltd | Método para identificar respondedores para degradadores de smarca2/4 |
| BR112022015004A2 (pt) * | 2020-01-29 | 2022-09-20 | Foghorn Therapeutics Inc | Composto, composição farmacêutica, métodos para diminuir a atividade de um complexo baf, induzir apoptose, reduzir o crescimento tumoral, suprimir a progressão e a colonização metastática do câncer e reduzir o nível e/ou a atividade de brg1 e/ou brm em um câncer e métodos de tratamento e de inibição de brm e brg1 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| EP4153176A4 (en) * | 2020-05-20 | 2024-05-29 | Foghorn Therapeutics Inc. | METHODS OF TREATING CANCER |
| BR112023002089A2 (pt) * | 2020-08-04 | 2023-02-28 | Aurigene Oncology Ltd | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 |
| JP2024509268A (ja) | 2021-03-09 | 2024-02-29 | フォグホーン セラピューティクス インコーポレイテッド | 結晶形、それらを含有する組成物、及びそれらの使用方法 |
| WO2024086577A1 (en) * | 2022-10-17 | 2024-04-25 | Foghorn Therapeutics Inc. | Methods of reducing or preventing metastases |
| CN116004644A (zh) * | 2023-01-19 | 2023-04-25 | 南京中澳转化医学研究院有限公司 | Smarca4突变体及其在结直肠癌药物开发中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2900301T3 (es) * | 2013-03-15 | 2022-03-16 | Novartis Ag | Biomarcadores asociados con la inhibición de BRM |
| WO2015005473A1 (ja) * | 2013-07-12 | 2015-01-15 | 独立行政法人国立がん研究センター | がんの治療への応答性を予測する方法 |
| WO2015103431A1 (en) * | 2013-12-31 | 2015-07-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2017214373A1 (en) * | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| JP2020508995A (ja) * | 2017-02-28 | 2020-03-26 | エピザイム，インコーポレイティド | 癌の処置のためのｓｍａｒｃａ２の阻害 |
| MX2021000881A (es) * | 2018-07-24 | 2021-06-08 | Epizyme Inc | Compuestos de piridin-2-ona utiles como antagonistas de smarca2. |
-
2018
- 2018-02-28 JP JP2019544887A patent/JP2020508995A/ja active Pending
- 2018-02-28 CA CA3054682A patent/CA3054682A1/en active Pending
- 2018-02-28 CN CN201880014651.2A patent/CN110366418A/zh active Pending
- 2018-02-28 BR BR112019017851-1A patent/BR112019017851A2/pt not_active Application Discontinuation
- 2018-02-28 SG SG11201907420VA patent/SG11201907420VA/en unknown
- 2018-02-28 US US16/489,489 patent/US20200069669A1/en not_active Abandoned
- 2018-02-28 SG SG10202109335T patent/SG10202109335TA/en unknown
- 2018-02-28 KR KR1020197028241A patent/KR20190140438A/ko not_active Ceased
- 2018-02-28 AU AU2018227774A patent/AU2018227774A1/en not_active Abandoned
- 2018-02-28 WO PCT/US2018/020124 patent/WO2018160636A1/en not_active Ceased
- 2018-02-28 MX MX2019010149A patent/MX2019010149A/es unknown
- 2018-02-28 EP EP18760511.8A patent/EP3589289A4/en not_active Withdrawn
-
2019
- 2019-08-13 IL IL26867619A patent/IL268676A/en unknown
- 2019-08-23 CL CL2019002427A patent/CL2019002427A1/es unknown
- 2019-08-26 MX MX2024000253A patent/MX2024000253A/es unknown
-
2022
- 2022-06-24 US US17/848,885 patent/US20230000849A1/en active Pending
- 2022-07-21 JP JP2022116375A patent/JP2022136149A/ja active Pending
-
2024
- 2024-04-12 AU AU2024202398A patent/AU2024202398A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klomp et al. | Defining the KRAS-and ERK-dependent transcriptome in KRAS-mutant cancers | |
| Walton et al. | PBRM1, SETD2 and BAP1—the trinity of 3p in clear cell renal cell carcinoma | |
| Zhang et al. | Oncological role of HMGA2 | |
| Laudato et al. | P53‐induced miR‐30e‐5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1 | |
| Miotto et al. | Selectivity of ORC binding sites and the relation to replication timing, fragile sites, and deletions in cancers | |
| Park et al. | Aicardi-Goutières syndrome-associated gene SAMHD1 preserves genome integrity by preventing R-loop formation at transcription–replication conflict regions | |
| Strub et al. | SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling | |
| Valente et al. | p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa | |
| García-Muse et al. | Transcription–replication conflicts: how they occur and how they are resolved | |
| Leszinski et al. | Relevance of histone marks H3K9me3 and H4K20me3 in cancer | |
| Ryu et al. | Heterochromatic breaks move to the nuclear periphery to continue recombinational repair | |
| Estève et al. | Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells | |
| Llabata et al. | Multi-omics analysis identifies MGA as a negative regulator of the MYC pathway in lung adenocarcinoma | |
| Kondo et al. | Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon‐inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation | |
| Tu et al. | Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence | |
| Chatterjee et al. | Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer | |
| Rashi-Elkeles et al. | Parallel profiling of the transcriptome, cistrome, and epigenome in the cellular response to ionizing radiation | |
| Chen et al. | Histone H2B monoubiquitination is a critical epigenetic switch for the regulation of autophagy | |
| Chen et al. | Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1 | |
| Shu et al. | The epigenetic modifier PBRM1 restricts the basal activity of the innate immune system by repressing retinoic acid‐inducible gene‐I‐like receptor signalling and is a potential prognostic biomarker for colon cancer | |
| de Nonneville et al. | TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT | |
| Li et al. | Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma | |
| Janus et al. | Pro-inflammatory cytokine and high doses of ionizing radiation have similar effects on the expression of NF-kappaB-dependent genes | |
| Kumar et al. | HAT3-mediated acetylation of PCNA precedes PCNA monoubiquitination following exposure to UV radiation in Leishmania donovani | |
| Bretz et al. | ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma |